Quick Answer
Outlook Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $8.08 million for the year ending 2025.
- Outlook Therapeutics, Inc. showed a decrease of -45.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Outlook Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on December 19, 2025.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Outlook Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 244.1%.
- Historical annual values: Fiscal year 2025: $8.08 million | Fiscal year 2024: $14.93 million | Fiscal year 2023: $23.39 million | Fiscal year 2022: $17.40 million | Fiscal year 2021: $14.48 million | Fiscal year 2020: $12.54 million | Fiscal year 2019: $8.02 million | Fiscal year 2018: $1.72 million | Fiscal year 2017: $3.19 million | Fiscal year 2016: $2.35 million | Fiscal year 2015: $9.07 million | Fiscal year 2014: $2.35 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: